UPDATE 2-Gilead working with China to test Ebola drug as new coronavirus treatment [Reuters]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Reuters
Gilead working with China to test Ebola drug as new coronavirus treatment (Reuters) - Gilead Sciences Inc said on Friday it provided its experimental Ebola therapy for use in a small number of patients with the coronavirus that has killed over 200 so far in China and is working with the country’s authorities to set up a study. The announcement comes a day after the World Health Organization declared the coronavirus epidemic a public health emergency of international concern. The company said it was also expediting laboratory testing of the antiviral drug, remdesivir, against samples of the new coronavirus, which has infected nearly 10,000 globally. Johnson & Johnson on Wednesday joined a growing list of drugmakers to begin work on developing a vaccine for the virus. Co-Diagnostics Inc said on Friday initial verification of its screening test designed to identify the presence of the coronavirus was successful. Shares of the company closed up 20.7%. Last week, director of the U.S. Natio
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at UBS Group AG from $70.00 to $96.00. They now have a "neutral" rating on the stock.MarketBeat
- Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Mizuho from $90.00 to $100.00. They now have an "outperform" rating on the stock.MarketBeat
- Gilead Sciences, Inc. (NASDAQ: GILD) was upgraded by analysts at Daiwa America to a "hold" rating.MarketBeat
- GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study [Yahoo! Finance]Yahoo! Finance
- How Gilead Is Driving Global Health Equity And Innovation [Forbes]Forbes
GILD
Earnings
- 11/6/24 - Beat
GILD
Sec Filings
- 11/20/24 - Form 8-K
- 11/15/24 - Form 424B5
- 11/13/24 - Form FWP
- GILD's page on the SEC website